ASCO GI 2020: Maintenance Capecitabine or Durvalumab Following First-Line Chemotherapy May Improve Outcomes in Advanced Gastroesophageal Adenocarcinoma
The comparative trial will continue to accrue patients.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.